Adverum Biotechnologies, Inc. (ADVM) News
Filter ADVM News Items
ADVM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ADVM News Highlights
- For ADVM, its 30 day story count is now at 2.
- Over the past 9 days, the trend for ADVM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ADVM are GENE, DEC and LUNA.
Latest ADVM News From Around the Web
Below are the latest news stories about ADVERUM BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate ADVM as an investment opportunity.
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula SocietyREDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. “We are very pleased to have the opportunity to present our initial Phase 2 efficacy and saf |
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx ConferenceREDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and Star Seyedkazemi, chief development officer of Adverum Biotechnologies, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Wednesday, November 29, 2023 at 3:50 p.m. |
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels observed in the OPTIC trial - - Reported OPTIC long-term follow-up data demonstrating that patients continue to experience substantial, long-term benefit from Ixo-vec through 3 years of follow-up - - Initial Phase 2 LUNA efficacy and safety data anticipated in Q4 2023 - - Cash runway projected into 2 |
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of DirectorsREDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023. Dr. Nicholson brings over forty years of pharmaceutical experience, a proven track record in drug development, and deep experience |
Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden - - 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose entirely free of injections at year 3 - - Durable aflibercept protein levels up to 4.5 years after a single Ixo-vec IVT injection - - Ixo-vec continues to be generally wel |
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ... |
Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 TrialAqueous Aflibercept Protein Expression Levels in LUNA and OPTIC Trials Aqueous aflibercept protein expression levels from LUNA and OPTIC trials at Week 14 and 12, respectively. - Initial aflibercept protein levels in LUNA suggest Ixo-vec at both the 2E11 and 6E10 doses delivers aflibercept protein levels within the therapeutically active range - - Ixo-vec has been well tolerated with a favorable preliminary safety profile - - Initial Phase 2 LUNA efficacy and safety data anticipated in Q4 2023 - |
Adverum Biotechnologies to Participate in Upcoming Investor ConferencesREDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Adverum Biotechnologies will present at the following upcoming investor conferences: Cantor Fitzgerald Global Healthcare Conference 2023 on Thursday, September 28, 2023 at 8:00 a.m. ET.Chardan’s 7th Annual Genetics Medicines Conference on Monday, Octo |
Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceREDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer of Adverum Biotechnologies, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023. The on-demand webcast corporate presentation may be accessed under Event |
Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology OfficerDr. Ramelmeier has more than 30 years of experience in drug development and clinical and commercial chemistry, manufacturing and controls (CMC), including gene and cell therapiesREDWOOD CITY, Calif., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that R. Andrew “Andy” Ramelmeier, Ph.D., has joined Adverum as the company’s ch |